Heart HealthLeft Atrial Appendage Closure vs Anticoagulation: Why Pooled Trial Data Can Mislead
Atrial fibrillation raises stroke risk, and most patients take long-term blood thinners. Left atrial appendage closure (LAAC) is a device procedure that seals off a small pouch in the heart where clots tend to form. It has been tested against anticoagulants in randomized trials enrolling more than 7,000 people. This JACC Evidence Review argues that the newest trials (OPTION, CLOSURE-AF, CHAMPION-AF) should not be lumped into one pooled result, because they enrolled different patients, used different comparators, devices, drug regimens and endpoints, and followed patients for different lengths of time. The authors conclude that anticoagulation remains the preferred first-line strategy for most eligible patients. LAAC is a reasonable option when long-term anticoagulation is unsafe or unsustainable, though trial evidence in that group is limited. Because the two approaches carry different kinds of risk, the choice should rest on shared decision-making. This summary is based on the abstract only.